AUSTRALIANS living with one of 200 chronic conditions may now be eligible to participate in what may well become the world's largest study into the economic impact of medicinal cannabis treatments on health and quality of life for patients.
The Global QUEST study, led by Curtin University and sponsored by ASX-listed medicinal cannabis supplier Little Green Pharma, will aim to assess whether medicinal cannabis reduces the economic impact of chronic disease, by reducing both the number of medications a patient requires and their need for healthcare services.
Lead researcher A/Prof Richard Norman, from the Curtin School of Population Health, said Global QUEST is looking into real health challenges faced by many.
"People living with chronic conditions such as pain, anxiety, insomnia and mood, development or movement disorders face significant challenges that impact their everyday life.
"Using medicinal cannabis as a treatment option can help to improve their outcomes and reduce their level of suffering and this study is an opportunity to quantify this," Norman explained.
"As part of the study, participants can access pharmaceutical-grade cannabis oils and flower medications made locally, as well as book a range of affordable, independent doctors who are experienced medical cannabis prescribers."
Pharmacists & patients can participate and learn more about the Global QUEST Initiative, HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Aug 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Aug 23
